IMPORTANT INFORMATION NB: Marten & Co has been paid to prepare this note on behalf of Home REIT Plc. This is a marketing communication and not a prospectus. The note is based upon publicly available information and information provided to us by Home REIT Plc and should be read in conjunction with the Home REIT […]
Economic & Political Roundup Kindly sponsored by Allianz A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell […]
The private equity sector company FastForward Innovations (FFWD), disruptive high growth businesses with near-term re-rating potential, has reported annual results to 31 March 2020. The net assets of the company were 8.8p, as at 31 March 2020, which represented a (25.3%) decline over the year. Highlights from FFWD’s investment portfolio Leap Gaming (gaming) delivered a 95% […]
Recovery on-hold, hold on The managers of CQS Natural Resources Growth Income Trust (CYN) say that the covid-19 pandemic has delayed, rather than ended, the recovery they were seeing in the mining sector. After sharp falls in March, share prices have recouped some of their losses, but the managers believe there is much more to […]
Recovery on-hold, hold on The managers of CQS Natural Resources Growth Income Trust (CYN) say that the pandemic has delayed, rather than ended, the recovery they were seeing in the mining sector. After sharp falls, April and May have seen share prices recoup some of their losses, but the managers believe there is much more […]
Economic & Political Roundup Kindly sponsored by Allianz A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell […]
BioPharma Credit (BPCR) has published annual results to 31 December 2019. The company says it is London’s only specialist debt investor to the life sciences industry. The company seeks to achieve returns for its shareholders primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences […]
Economic & Political Roundup
Trust favourite Vertex holds industry’s most valuable R&D asset Investment trust favourite Vertex Pharmaceuticals (Nasdaq: VRTX) holds the pharma/biotech industry’s most valuable R&D asset, according to calculations from the industry consultancy Evaluate. The US firm’s triple therapy of VX-445/tezacaftor/ivacaftor, which is in Phase III studies for cystic fibrosis and on track for a launch next […]
HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked […]
